(NASDAQ: RNXT) Renovorx's forecast annual revenue growth rate of 151.22% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.45%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Renovorx's revenue in 2026 is $1,976,000.On average, 6 Wall Street analysts forecast RNXT's revenue for 2026 to be $178,261,557, with the lowest RNXT revenue forecast at $162,421,099, and the highest RNXT revenue forecast at $191,574,761. On average, 6 Wall Street analysts forecast RNXT's revenue for 2027 to be $526,300,322, with the lowest RNXT revenue forecast at $442,269,178, and the highest RNXT revenue forecast at $663,945,322.
In 2028, RNXT is forecast to generate $1,543,384,044 in revenue, with the lowest revenue forecast at $1,037,030,964 and the highest revenue forecast at $2,275,520,052.